Long-Term Partial Remission with Capecitabine/ Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone
暂无分享,去创建一个
G. von Minckwitz | K. Bürrig | C. Uleer | C. Moisidis-Tesch | Jasmin Yazdan-Pourfard | Bernhard Holland
[1] S. Loibl,et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Giordano,et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer , 2008, Breast Cancer Research.
[3] G. Viani,et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials , 2007, BMC Cancer.
[4] J. Isola,et al. Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance , 2007, Molecular Cancer Therapeutics.
[5] V. Heinemann,et al. Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC) , 2005, Oncology Research and Treatment.
[6] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Carey. Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients With Primary Operable Breast Tumors Overexpressing HER2 , 2005 .
[8] S. Ménard,et al. Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.
[9] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.